N. Brutsche

发表

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Paul J Carlson, D. Luckenbaugh, H. Manji, 2006, Archives of general psychiatry.

Synaptic Potentiation Is Critical for Rapid Antidepressant Response to Ketamine in Treatment-Resistant Major Depression

C. Grillon, M. Furey, C. Zarate, 2012, Biological Psychiatry.

Ketamine Has Distinct Electrophysiological and Behavioral Effects in Depressed and Healthy Subjects

E. Ballard, A. Nugent, T. Gould, 2017, Molecular Psychiatry.

Neural Correlates of Rapid Antidepressant Response to Ketamine in Treatment-Resistant Unipolar Depression: A preliminary PET study

W. Drevets, D. Luckenbaugh, A. Nugent, 2013 .

Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression.

D. Luckenbaugh, C. Zarate, D. Mager, 2012, British journal of clinical pharmacology.

Acute Stress Symptoms Do Not Worsen in Posttraumatic Stress Disorder and Abuse with a Single Subanesthetic Dose of Ketamine

D. Luckenbaugh, D. Ionescu, C. Zarate, 2013, Biological Psychiatry.

Relationship of Ketamine's Plasma Metabolites with Response, Diagnosis, and Side Effects in Major Depression

G. Laje, D. Luckenbaugh, C. Zarate, 2012, Biological Psychiatry.

Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression

E. Ballard, D. Luckenbaugh, D. Ionescu, 2015, Neural plasticity.

A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression

Carlos A. Zarate, David A. Luckenbaugh, Lobna Ibrahim, 2013, Biological Psychiatry.

D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression

D. Luckenbaugh, C. Zarate, R. Machado-Vieira, 2014, Psychopharmacology.

Neural Correlates of Rapid Antidepressant Response to Ketamine in Treatment-Resistant Unipolar Depression: A Preliminary Positron Emission Tomography Study

Peter Herscovitch, Allison C. Nugent, Wayne C. Drevets, 2013, Biological Psychiatry.

Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials.

E. Ballard, D. Luckenbaugh, C. Zarate, 2017, Journal of affective disorders.

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.

D. Luckenbaugh, H. Manji, C. Zarate, 2010, Archives of general psychiatry.

A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder

D. Luckenbaugh, C. Zarate, N. Brutsche, 2012, Journal of clinical psychopharmacology.

Ketamine’s Antidepressant Efficacy is Extended for at Least Four Weeks in Subjects with a Family History of an Alcohol Use Disorder

M. Furey, E. Ballard, D. Luckenbaugh, 2014, The international journal of neuropsychopharmacology.

Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial

D. Luckenbaugh, A. Cravchik, C. Zarate, 2012, Biological Psychiatry.

Neural correlates of rapid antidepressant response to ketamine in bipolar disorder

W. Drevets, D. Luckenbaugh, A. Nugent, 2014, Bipolar disorders.

Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study

D. Luckenbaugh, H. Manji, C. Zarate, 2012, Neuropsychopharmacology.

Family History of Alcohol Dependence and Initial Antidepressant Response to an N-methyl-D-aspartate Antagonist

D. Luckenbaugh, C. Zarate, H. Manji, 2009, Biological Psychiatry.

Do the dissociative side effects of ketamine mediate its antidepressant effects?

D. Luckenbaugh, D. Ionescu, C. Zarate, 2014, Journal of affective disorders.

Motor-Activity Markers of Circadian Timekeeping Are Related to Ketamine’s Rapid Antidepressant Properties

E. Ballard, C. Zarate, N. Brutsche, 2017, Biological Psychiatry.

Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.

G. Tononi, H. Manji, F. Ferrarelli, 2013, The international journal of neuropsychopharmacology.

Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.

D. Luckenbaugh, H. Manji, C. Zarate, 2009, The Journal of clinical psychiatry.

Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.

D. Luckenbaugh, C. Zarate, R. Machado-Vieira, 2010, The Journal of clinical psychiatry.

Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.

E. Ballard, D. Luckenbaugh, C. Zarate, 2018, Journal of affective disorders.

Rapid Resolution of Suicidal Ideation after a Single Infusion of an NMDA Antagonist in Patients with Treatment-Resistant Major Depressive Disorder

D. Luckenbaugh, C. Zarate, R. Machado-Vieira, 2010 .

Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration

Jennifer W. Evans, A. Nugent, C. Zarate, 2018, Biological Psychiatry.

Baseline Vitamin B12 and Folate Levels Do Not Predict Improvement in Depression After a Single Infusion of Ketamine

D. Luckenbaugh, D. Ionescu, C. Zarate, 2014, Pharmacopsychiatry.

D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression

D. Luckenbaugh, C. Zarate, R. Machado-Vieira, 2014, Psychopharmacology.

Are 24-hour motor activity patterns associated with continued rapid response to ketamine?

E. Ballard, N. Brutsche, Lawrence T. Park, 2018, Neuropsychiatric disease and treatment.

The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder

F. McMahon, E. Ballard, D. Luckenbaugh, 2017, Journal of psychopharmacology.

Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder.

C. Zarate, S. Sarasso, N. Brutsche, 2013, Journal of affective disorders.

Clinical predictors of ketamine response in treatment-resistant major depression.

D. Luckenbaugh, D. Ionescu, C. Zarate, 2014, The Journal of clinical psychiatry.

Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales.

D. Luckenbaugh, C. Zarate, N. Brutsche, 2015, Journal of psychiatric research.

Riluzole likely lacks antidepressant efficacy in ketamine non-responders.

M. Furey, E. Ballard, D. Luckenbaugh, 2014, Journal of psychiatric research.

Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.

D. Luckenbaugh, D. Ionescu, C. Zarate, 2014, The Journal of clinical psychiatry.

Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.

D. Luckenbaugh, C. Zarate, N. Brutsche, 2012, Bipolar disorders.

Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients

F. McMahon, G. Laje, C. Zarate, 2012, Biological Psychiatry.

Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety.

M. Furey, E. Ballard, D. Luckenbaugh, 2014, Journal of psychiatric research.

Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant.

E. Ballard, D. Luckenbaugh, C. Zarate, 2015, Journal of psychiatric research.

A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression

D. Luckenbaugh, C. Zarate, Mark A. Smith, 2013, Biological Psychiatry.